In a successful week for the medical technology companies in the LSI Alumni community, we saw the LSI Alumni raise new funding, appoint new executives, emerge from stealth, and much more on the road to LSI Europe ’24 in Sintra, Portugal (Sept 16-20).
Backpack Healthcare
Received a $1.1M grant funded by the Maryland Community Health Resources Commission to provide vital support to students, families, and caregivers within Howard County Public Schools. Backpack Healthcare is a leading provider of mental health services, focusing on innovative care and community partnerships to support children, teens, and families.
Cairn Surgical
Closed $4.5M in a Series A2 financing, led by Morningside Ventures. The company is developing patient-specific guides using patient imaging data and state-of-the-art 3D printing technologies that are commercially available in Europe and being studied in a U.S. pivotal trial.
Diality
Announced the appointment of Dr. Jennifer Joe as Vice President, Medical Affairs. The company’s Moda-flx Hemodialysis System provides clinicians the flexibility to easily customize each hemodialysis experience according to patient needs in one integrated system.
Endovascular Engineering
Announced the appointment of Dan Rose as Chief Executive Officer. The company’s Hēlo Thrombectomy System is designed to remove clots with its patented dual-action approach that simultaneously combines the power of aspiration with advanced mechanical clot disruption.
IKONA Health
Announced a collaborative study with Dialysis Education Services and Lifeliqe to evaluate the impact of Lifeliqe’s virtual reality product on dialysis workforce training programs conducted by DES. This partnership focuses on assessing the effectiveness of VR tools in improving training outcomes, with a particular emphasis on workforce engagement, recruitment, and retention.
MAUI Imaging
Emerged from stealth and announced a $4 million contract with the Department of Defense. The company’s mission is to offer easy-to-use patient-safe imaging systems that aim to provide physicians with real-time imaging of all tissue types to aid in effective patient diagnostics and guidance to improve clinical outcomes and save lives regardless of environment or infrastructure
Minerva Surgical
Announced the appointment of Darin Hammers as New CEO. The company is focused on developing, manufacturing, distributing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
Navigation Sciences
Selected as ‘Best Start-Up’ candidate by the Prix Galien Foundation. The company is capitalizing on the emergence of low dose CT scanning to detect early-stage lung tumors and clinical studies demonstrating that surgical removal of less tissue in early-stage lung cancer, with appropriate margins, can be curative.
Nitinotes
Announced the appointment of Lloyd Diamond as new CEO. The company’s flagship product, EndoZip™, offers a minimally invasive approach for obesity class I & II patients, ensuring consistent, safe suturing with the press of a button.
Proprio
Announced the appointment of Bryan Humbarger as Chief Commercial Officer. The company is advancing surgery through a proprietary platform that synthesizes artificial intelligence, computer vision, and augmented reality.
Vascular Perfusion Solutions
Awarded a $160,000 seed grant from the Consortium for Technology & Innovation in Pediatrics (CTIP) Accelerator. The VP.S ENCORE® is a hypothermic machine perfusion device for prolonged cardiac graft preservation.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
In a successful week for the medical technology companies in the LSI Alumni community, we saw the LSI Alumni raise a Series C funding round, receive FDA Breakthrough Designation, add new board members, and much more on the road to LSI Europe ’24 in Sintra, Portugal (Sept 16-20).
Caresyntax
Raised a $180M Series C extension and growth debt expansion round. The company is transforming surgery by implementing a scalable, end-to-end software and AI platform, allowing the capture and use of novel data and applications to improve precision and safety.
Colospan
Received FDA Breakthrough Device Designation for its Intraluminal Bypass Device. The CG-100 Intraluminal Bypass Device is a single-use, temporary intraluminal bypass device, intended for patients with colorectal cancer requiring an anastomosis and are to receive a protective stoma under routine clinical practice.
Diality
Joined Kidney Care Partners, a leading kidney care multi-stakeholder coalition representing patient advocates, physician organizations, health professional groups, dialysis providers, researchers, and manufacturers. The Moda-flx Hemodialysis System provides clinicians the flexibility to easily customize each hemodialysis experience according to patient needs in one integrated system.
Invenio Imaging
Announced first patients enrolled in US pivotal study of its AI-based image analysis module for lung cancer. The company is dedicated to advancing the care of cancer patients by combining intraoperative fresh tissue imaging and artificial intelligence.
Lindera
Successfully completed the Stage 2 audit under the EU Medical Device Regulation for the company’s mobility analysis and fall prevention technology. The company specializes in advanced AI-based 3D motion tracking and analysis solutions using ubiquitous smartphone cameras to address the critical challenge of fall prevention in the aging population.
Linshom Medical
Completed clinical study enrollment of 508 patients well ahead of schedule at The Ohio State University Wexner Medical Center. The company’s patented and FDA cleared sensor provides a predictive (vs. responsive) respiratory profile including Respiratory Rate (RR), relative Tidal Volume (rTV) and Seconds Since Last Breath (SSLB) that are all delivered continuously and in real time.
Medical 21
Raised $2.5M as it pursues a new type of artificial artery for bypass surgery. The company is reshaping cardiac bypass surgery through its less-invasive, innovative artificial graft technology.
PanTher Therapeutics
Received FDA clearance of its Investigational New Drug (IND) application for PTM-101 to treat pancreatic cancer patients, a population with challenging diagnoses and limited treatment options. PTM-101, has successfully been evaluated in a Phase 1 clinical trial in treatment naïve, localized non-metastatic pancreatic cancer patients.
Pulse BioSciences
Announced the appointment of LSI Alumni Paul LaViolette to its Board of Directors. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue.
restor3d
Announced its strategic expansion into the field of robotics and navigation through the appointment of seasoned leaders, Larry Hazbun, Senior Vice President of Robotics, and Kirstin Widding, Senior Vice President of Hip & Knee. The company holds proprietary expertise and intellectual property in 3D printing of osseointegrative materials, AI-based planning and design automation tools, and digital health solutions to provide seamless data-backed care to optimize individual patient outcomes.
Samay
Awarded a $500K SBIR Phase IIb grant from the National Science Foundation. With this new grant, Samay’s total funding reaches $4.9 million, with over half of that amount being non-dilutive capital.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in our Weekly Recap, and follow our blog for the latest medical device news and advancements.
About Life ScIence Intelligence (LSI)
LSI helps medtech leaders access the intelligence and relationships needed to build businesses that save lives. For over 15 years, medtech’s global leaders have trusted LSI for research and data insights on emerging technology, global markets, and more. Now in their fifth year, LSI Emerging Medtech Summits in the USA and Europe have become the epicenter of the industry, bringing together the global innovators, investors, and strategics that are moving medtech forward. Based in Huntington Beach, California, LSI is building an enduring company to impact millions of people’s health.
For more information, visit www.ls-intel.com and follow Life Science Intelligence – LSI on LinkedIn.
Media Contact: Henry Peck, hpeck@LS-intel.com, 714-847-3540
SOURCE Life Science Intelligence